Crossmark

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases

Crossref DOI link: https://doi.org/10.1186/s12885-019-5287-z

Published Online: 2019-01-30

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Darlix, Amélie https://orcid.org/0000-0003-1384-1709
Hirtz, Christophe

Thezenas, Simon

Maceski, Aleksandra

Gabelle, Audrey

Lopez-Crapez, Evelyne

De Forges, Hélène

Firmin, Nelly

Guiu, Séverine

Jacot, William

Lehmann, Sylvain
Funding

Funding for this research was provided by:

GEFLUC (Groupement des Entreprises Françaises dans la Lutte contre le Cancer) Languedoc-Roussillon

SIRIC Montpellier Cancer (INCa-DGOS-Inserm 6045)
License Information

Text and Data Mining valid from 2019-01-30
More Information

Article History

Received: 3 April 2018

Accepted: 7 January 2019

First Online: 30 January 2019

Ethics approval and consent to participate

: This study was reviewed and approved by the Montpellier Cancer Institute Institutional Review Board. Considering the retrospective, non-interventional nature of this study, no specific consent was deemed necessary by the clinical research review board of the Montpellier Cancer Institute.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.